Indirect and Direct Mapping of the Cancer-Specific EORTC QLQ-C30 onto EQ-5D-5L Utility Scores

被引:7
作者
Meunier, Aurelie [1 ]
Soare, Alexandra [1 ]
Chevrou-Severac, Helene [2 ]
Myren, Karl-Johan [2 ]
Murata, Tatsunori [3 ]
Longworth, Louise [1 ]
机构
[1] PHMR Ltd, London NW1 8XY, England
[2] Alex Pharma GmbH, Zurich, Switzerland
[3] CRECON Res & Consulting Inc, Tokyo, Japan
关键词
QUALITY-OF-LIFE; COMPLEMENT INHIBITOR ECULIZUMAB; MIXTURE REGRESSION-MODELS; EUROPEAN-ORGANIZATION; QUESTIONNAIRE; VALUES;
D O I
10.1007/s40258-021-00682-0
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objective The aim of this study was to develop a response mapping algorithm to predict EQ-5D-5L utilities from European Organisation for Research and Treatment Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) scores and compare performance with direct mapping approaches to identify the best performing algorithm. Methods The Multi-Instrument Comparison dataset contains responses to both the EQ-5D-5L and QLQ-C30 questionnaires from 692 individuals with a broad range of cancers. Response mapping was conducted, fitting ordered logistic regressions to predict response levels for each of the five EQ-5D dimensions and utilities were predicted using the US and Japanese EQ-5D-5L value sets to test the algorithm performance. Various direct mapping models were fitted: ordinary least squares, tobit, two-part (TPM), adjusted limited dependent variable mixture and beta mixture models. Model assessment and recommendations regarding the best mapping algorithm was based on goodness-of-fit statistics, predictive ability (measures of error, distribution of predicted utilities) and in sample cross-validation. Results The response mapping model performed well in terms of predictive ability and measurement error using the US or Japanese value set, with mean absolute error ranging from 0.0708 to 0.0988, and comparably to the TPM, which was the best performing direct algorithm. Conclusion The developed mapping algorithms enable the prediction of EQ-5D-5L utilities from QLQ-C30 scores when EQ-5D-5L data have not been directly collected in clinical trials. The response mapping model offers the possibility of predicting EQ-5D-5L utility values using any national value set and can be generalised to multiple countries and oncology settings.
引用
收藏
页码:119 / 131
页数:13
相关论文
共 45 条
  • [1] THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY
    AARONSON, NK
    AHMEDZAI, S
    BERGMAN, B
    BULLINGER, M
    CULL, A
    DUEZ, NJ
    FILIBERTI, A
    FLECHTNER, H
    FLEISHMAN, SB
    DEHAES, JCJM
    KAASA, S
    KLEE, M
    OSOBA, D
    RAZAVI, D
    ROFE, PB
    SCHRAUB, S
    SNEEUW, K
    SULLIVAN, M
    TAKEDA, F
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) : 365 - 376
  • [2] Mapping the EQ-5D index from the cystic fibrosis questionnaire-revised using multiple modelling approaches
    Acaster, Sarah
    Pinder, Binny
    Mukuria, Clara
    Copans, Amanda
    [J]. HEALTH AND QUALITY OF LIFE OUTCOMES, 2015, 13
  • [3] Tails from the Peak District: Adjusted Limited Dependent Variable Mixture Models of EQ-5D Questionnaire Health State Utility Values
    Alava, Monica Hernandez
    Wailoo, Allan J.
    Ara, Roberta
    [J]. VALUE IN HEALTH, 2012, 15 (03) : 550 - 561
  • [4] Mapping EORTC-QLQ-C30 and QLQ-CR29 onto EQ-5D-5L in Colorectal Cancer Patients
    Ameri, Hosein
    Yousefi, Mahmood
    Yaseri, Mehdi
    Nahvijou, Azin
    Arab, Mohammad
    Akbari Sari, Ali
    [J]. JOURNAL OF GASTROINTESTINAL CANCER, 2020, 51 (01) : 196 - 203
  • [5] Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients
    Ameri, Hosein
    Yousefi, Mahmood
    Yaseri, Mehdi
    Nahvijou, Azin
    Arab, Mohammad
    Sari, Ali Akbari
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2019, 19 (01) : 89 - 96
  • [6] A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures
    Brazier, John E.
    Yang, Yaling
    Tsuchiya, Aki
    Rowen, Donna Louise
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2010, 11 (02) : 215 - 225
  • [7] Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria
    Brodsky, Robert A.
    Young, Neal S.
    Antonioli, Elisabetta
    Risitano, Antonio M.
    Schrezenmeier, Hubert
    Schubert, Jorg
    Gaya, Anna
    Coyle, Luke
    De Castro, Carlos
    Fu, Chieh-Lin
    Maciejewski, Jaroslaw P.
    Bessler, Monica
    Kroon, Henk-Andre
    Rother, Russell P.
    Hillmen, Peter
    [J]. BLOOD, 2008, 111 (04) : 1840 - 1847
  • [8] Paroxysmal nocturnal hemoglobinuria
    Brodsky, Robert A.
    [J]. BLOOD, 2014, 124 (18) : 2804 - 2811
  • [9] A Systematic Review of Studies Comparing the Measurement Properties of the Three-Level and Five-Level Versions of the EQ-5D
    Buchholz, Ines
    Janssen, Mathieu F.
    Kohlmann, Thomas
    Feng, You-Shan
    [J]. PHARMACOECONOMICS, 2018, 36 (06) : 645 - 661
  • [10] Devlin NJ, 2017, J CANCER POLICY, V11, P19, DOI 10.1016/j.jcpo.2016.09.005